日本学龄前儿童百日咳加强疫苗接种的成本效果分析
日本正考虑在现行四剂DTaP疫苗程序基础上增加第五剂。该经济模型分析比较6岁儿童加强接种与不加强接种策略的成本和效果,并模拟未接种婴儿通过家庭内传播获得的间接保护。结果显示,加强策略每获得一个QALY的增量成本效果比为71,605,491日元(656,931美元),敏感性分析中无变量可使ICER降至阈值以下;结论认为该加强接种可减少目标人群百日咳病例,但就未接种婴儿的群体免疫而言不具成本效果。
要点
- 日本现行常规免疫为四剂DTaP疫苗,第五剂加强接种正在考虑中。
- 6岁儿童加强接种每获得一个QALY的ICER为71,605,491日元(656,931美元)。
- 敏感性分析中无变量可使ICER低于每QALY 5,000,000日元的阈值。
核心结论
- 将DTaP加强疫苗纳入常规免疫程序可望减少目标人群的百日咳病例数。
- 在日本为6岁儿童增加加强接种,就实现未接种婴儿的群体免疫而言不具成本效果。
研究设计与样本
- 经济模型分析,比较6岁儿童DTaP第五剂加强接种策略与不加强接种策略的成本和效果,效果指标为质量调整生命年(QALY)。
- 模型包含两个子模型:一个针对6岁及以上儿童,一个针对3个月以下婴儿;婴儿的群体免疫通过同一家庭内兄弟姐妹感染来建模。
主要发现
- 从社会视角看,加强策略每获得一个QALY的增量成本效果比(ICER)为71,605,491日元(656,931美元)。
- 增量QALY中7.10%(0.0000934)来自婴儿感染的减少。
- 敏感性分析中无变量可使ICER低于每QALY 5,000,000日元的阈值;百日咳病程和百日咳发病率对ICER有显著影响。
- 当百日咳疾病负担降低时,与不加强策略相比,加强策略获得的QALY更少且成本更高。
关键数值与推荐
- 成本效果阈值为每获得一个QALY 5,000,000日元。
- 加强策略的ICER为每获得一个QALY 71,605,491日元(656,931美元),高于上述阈值。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Japan currently recommends four doses of the diphtheria-tetanus-acellular pertussis (DTaP) vaccine in its routine vaccination program, but the introduction of a fifth dose is currently under consideration. An objective of the booster vaccination is to prevent severe cases of pertussis in infants through herd immunity. Thus, the aim of this analysis was to demonstrate the cost-effectiveness of a fifth-dose of the DTaP vaccine for 6-year-old children, taking herd immunity for unvaccinated infants into account. METHOD: An economic model analysis was conducted comparing the cost and effectiveness of the two strategies based on quality-adjusted life years (QALYs). We evaluated the incremental cost-effectiveness ratio (ICER) of the booster strategy to the no booster strategy. This model contained two sub-models: one for children aged 6 years or older and one for infants under 3 months old. Herd immunity for infants is modeled as when siblings in the same family are infected. RESULTS: The ICER was JPY 71,605,491 (USD 656,931) per QALY gained from the societal perspective, and 7.10% of incremental QALYs (0.0000934) were from a reduction in infant infection. In the sensitivity analysis, no variables moved the ICER under the threshold (JPY 5,000,000 per QALY gained), and the duration of pertussis disease and the incidence rate of pertussis had a significant impact on the ICER. When the disease burden of pertussis decreased, the booster strategy resulted in fewer QALYs gained and greater costs compared with the no booster strategy. CONCLUSION: The introduction of a DTaP booster vaccination to the routine immunization schedule can be expected to reduce the number of pertussis cases in the target population. However, our study showed that adding a booster vaccination for 6-year-old children to the schedule in Japan would not be cost-effective in terms of achieving herd immunity among unvaccinated infants.
引用
- Tanaka M, Okubo R, Hoshi SL, et al. Cost-effectiveness of pertussis booster vaccination for preschool children in Japan. Vaccine. 2022. PMID: 35039195. doi:10.1016/j.vaccine.2022.01.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。